Assessing the Patient Experience in Cancer Care
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Communication is an important component of comprehensive cancer care impacting patient satisfaction, adherence, and quality of life. The wide array of issues addressed in cancer clinical interactions makes communicating about a broad range of topics (including quality of life, communication, symptom control, complementary/alternative therapies, costs, treatment burden, prognosis, anxiety, side-effects, sexual function, palliative care options, etc.) especially interesting and potentially challenging. Some of these topics may not be routinely addressed in the clinical interaction or may require consultative support from other members of the comprehensive cancer care team. One frequently overlooked critical element in research on communication between cancer clinicians, their patients, and their primary care clinicians is describing real-time consultations between patients and their clinicians. These interactions provide rich material for assessing key psycho-social dynamics and identifying issues that patients find important in their care. In order to devise systems of care that optimize the patient experience, it is critical that clinicians and researchers understand, appreciate, and systematically characterize the richness and complexity of the decision-making process in routine cancer consultations between cancer patients and their treating clinicians. This study seeks to assess the patient experience in cancer care by observing patients and their physicians in their clinical interactions and following them for several months to see how their care went. By describing in-depth the conversations and experiences of patients in these clinical interactions, this study will lay the foundation for practice-based interventions to optimize patients' interactions with their cancer care teams.
| Condition |
|---|
|
Brain Neoplasm Breast Neoplasm Endocrine Gland Neoplasm Gastrointestinal Neoplasm Genitourinary Neoplasm Gynecological Neoplasm Head and Neck Neoplasm Lung Neoplasm Melanoma Sarcoma |
| Study Type: | Observational |
| Official Title: | Assessing the Patient Experience in Cancer Care: An Observational Communication Study |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Cancer patients age 18 or over receiving care from clinicians who have also consented to participate in this study at Mayo Clinic Rochester, University of Southern California-Norris, or LA County Hospital.
Inclusion Criteria:
- Age greater than or equal to 18 years
- Histological confirmation of: brain, breast, endocrine, gastrointestinal, genitourinary, gynecological, head/neck, lung, melanoma, or sarcoma malignancies.
- Speak English or Spanish
- Not enrolled in hospice
- In any of the following phases of the cancer control continuum: initial diagnosis, initial treatment, early survivorship, or recurrence.
- Provide written informed consent
Exclusion Criteria:
Contacts and Locations| Contact: Katherine James, MPH | 507-293-0707 | james.katherine@mayo.edu |
| United States, California | |
| University of Southern California - Norris | Not yet recruiting |
| Los Angeles, California, United States, 90033 | |
| Los Angeles County Hospital | Not yet recruiting |
| Los Angeles, California, United States, 90033 | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Katherine James 507-293-0707 | |
| Principal Investigator: Jon C Tilburt, MD | |
| Principal Investigator: | Jon C Tilburt, MD, MPH | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Jon C. Tilburt, PI, Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01621295 History of Changes |
| Other Study ID Numbers: | 11-006682, R01AT006515 |
| Study First Received: | June 14, 2012 |
| Last Updated: | January 16, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Brain Neoplasms Breast Neoplasms Neoplasms Endocrine Gland Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Head and Neck Neoplasms Lung Neoplasms Melanoma Urogenital Neoplasms Sarcoma Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Breast Diseases Skin Diseases Endocrine System Diseases Digestive System Diseases Gastrointestinal Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
ClinicalTrials.gov processed this record on May 19, 2013